Physician profile
Miles B Andrew
NPI 1689692188
$4,621.10
in general payments reported to CMS, 2019-2025
21 companies · $956 in 2025
The $956 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.30 · 2020: $11.88 · 2021: $129 · 2022: $516 · 2023: $1,858 · 2024: $1,062 · 2025: $956.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,692 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,691.65 |
| Education | $184.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $898.24 | 2022-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $681.24 | 2022-2025 | |
| Janssen Biotech, INC. | $403.29 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $364.70 | 2022-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $329.55 | 2022-2025 | Ilumya |
| Lilly USA, LLC | $321.45 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $295.03 | 2023-2025 | Otezla, Otezla, Uplizna |
| Regeneron Healthcare Solutions, INC. | $280.81 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $251.94 | 2022-2025 | |
| Strata Skin Sciences, INC. | $192.43 | 2023 | Xtrac |
| Incyte Corporation | $129.61 | 2022-2025 | Opzelura |
| Ucb, INC. | $120.39 | 2019-2024 | Bimzelx |
| Galderma Laboratories, L.P. | $84.10 | 2025 | Nemluvio |
| Fresenius Kabi USA, LLC | $62.17 | 2023 | Idacio |
| Pfizer INC. | $55.77 | 2020-2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $34.71 | 2019 | |
| Genentech USA, INC. | $31.72 | 2022-2023 | Xolair |
| Leo Pharma INC. | $26.38 | 2022 | |
| Organogenesis INC. | $23.05 | 2023 | Puraply |
| Mallinckrodt Hospital Products INC. | $21.18 | 2024 | Acthar |
| Dermavant Sciences, INC. | $13.34 | 2023 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miles Andrew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.